Codexis and Axolabs Sign Agreement to Evaluate ECO Synthesis Manufacturing Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Codexis and Axolabs, part of LGC Group, an oligonucleotide Contract Research Development and Manufacturing organization, announced that they have entered into an agreement under which Axolabs will evaluate Codexis' ECO Synthesis Manufacturing Platform. This partnership provides Axolabs access to an innovative, scalable RNA manufacturing solution powered by enzymatic synthesis. The Agreement paves the way for future licensing discussions and potentially broader adoption of the platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDXS
Wall Street analysts forecast CDXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDXS is 6.00 USD with a low forecast of 2.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.290
Low
2.00
Averages
6.00
High
11.00
Current: 1.290
Low
2.00
Averages
6.00
High
11.00
No data
About CDXS
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Codexis Partners with Axolabs to Evaluate RNA Manufacturing Platform
- Partnership Agreement: Codexis and Axolabs have signed an agreement for Axolabs to evaluate Codexis' ECO Synthesis Manufacturing Platform, aimed at enhancing the efficient manufacturing of RNA therapeutics, which is expected to significantly improve market access capabilities.
- Technological Innovation: The platform utilizes enzymatic synthesis technology, enabling more sustainable and cost-effective production to meet large-scale manufacturing demands, thereby enhancing both companies' competitiveness in the nucleic acid therapeutics sector.
- Market Potential: Codexis CEO Alison Moore stated that this collaboration will expand the reach of the ECO Synthesis Manufacturing Platform, helping to meet the rapidly growing demand for nucleic acid drugs and potentially paving the way for future licensing discussions.
- Industry Leadership: The combination of Axolabs' technological leadership and Codexis' innovative capabilities reinforces both companies' commitment to providing high-quality oligonucleotide medicines globally, driving the industry towards more efficient manufacturing models.
Continue Reading
Codexis Partners with Axolabs to Enhance RNA Manufacturing with ECO Synthesis Platform
- Partnership Agreement: Codexis and Axolabs have entered into an agreement for Axolabs to evaluate Codexis' ECO Synthesis Manufacturing Platform, marking a strategic collaboration in efficient RNA manufacturing that is expected to pave the way for future licensing discussions and broader platform adoption.
- Innovation Potential: Axolabs' Senior Director of Operations noted that this technology could be pivotal for large-scale manufacturing of therapeutic oligonucleotides, enabling more sustainable and cost-effective production, which aligns with market demands for high-quality drugs.
- Market Expansion Strategy: Codexis CEO Alison Moore emphasized the mission to expand the reach of the ECO Synthesis Manufacturing Platform through collaborations with leading CDMOs, thereby enhancing the company's competitive position in the rapidly growing RNA therapeutics market.
- Global Drug Accessibility: This collaboration not only reinforces the commitment of both Codexis and Axolabs to excellence but also aims to enhance global access to high-quality oligonucleotide-based medicines, addressing the increasing market demand.
Continue Reading